| 000 | 01906 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250516004530.0 | ||
| 264 | 0 | _c20110923 | |
| 008 | 201109s 0 0 eng d | ||
| 022 | _a1569-8041 | ||
| 024 | 7 |
_a10.1093/annonc/mdq457 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGiralt, S A | |
| 245 | 0 | 0 |
_aThree palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantation. _h[electronic resource] |
| 260 |
_bAnnals of oncology : official journal of the European Society for Medical Oncology _cApr 2011 |
||
| 300 |
_a939-946 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Agents, Alkylating _xadministration & dosage |
| 650 | 0 | 4 |
_aDexamethasone _xadministration & dosage |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHematopoietic Stem Cell Transplantation |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aIsoquinolines _xadministration & dosage |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMelphalan _xadministration & dosage |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMultiple Myeloma _xdrug therapy |
| 650 | 0 | 4 |
_aNausea _xchemically induced |
| 650 | 0 | 4 | _aPalonosetron |
| 650 | 0 | 4 |
_aQuinuclidines _xadministration & dosage |
| 650 | 0 | 4 |
_aVomiting _xchemically induced |
| 700 | 1 | _aMangan, K F | |
| 700 | 1 | _aMaziarz, R T | |
| 700 | 1 | _aBubalo, J S | |
| 700 | 1 | _aBeveridge, R | |
| 700 | 1 | _aHurd, D D | |
| 700 | 1 | _aMendoza, F L | |
| 700 | 1 | _aRubenstein, E B | |
| 700 | 1 | _aDeGroot, T J | |
| 700 | 1 | _aSchuster, M W | |
| 773 | 0 |
_tAnnals of oncology : official journal of the European Society for Medical Oncology _gvol. 22 _gno. 4 _gp. 939-946 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1093/annonc/mdq457 _zAvailable from publisher's website |
| 999 |
_c20239115 _d20239115 |
||